What are the best longevity startups?

This blog post has been written by the person who has mapped the longevity tech market in a clean and beautiful presentation

The longevity startup ecosystem has transformed into a $8.49 billion market in 2024, with a handful of deep-science biotechs and platform companies commanding the innovation frontier.

From cellular reprogramming pioneers like Altos Labs securing $3 billion in funding to AI-driven discovery platforms revolutionizing drug development, the sector attracts both tech titans and pharmaceutical giants seeking the next breakthrough in human healthspan extension.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What startups are currently considered the most promising in the longevity space globally?

Altos Labs dominates the cellular reprogramming field with $3 billion in backing from Jeff Bezos and Yuri Milner, focusing on Yamanaka factor-based partial reprogramming to reverse cellular aging.

BioAge Labs leverages AI-driven target discovery using human aging data, attracting support from major pharmaceutical players including Sofinnova, Lilly Ventures, and Amgen Ventures for their platform approach to drug development.

Rubedo Life Sciences stands out in senotherapeutics with their GPX4 modulator RLS-1496, securing $40 million from Khosla Ventures and Ahren Innovation Capital for their Alembic platform that uses single-cell multi-omics to identify novel senolytic compounds.

Function Health has positioned itself as the leader in personalized prevention platforms, raising $53 million from Andreessen Horowitz Bio + Health and Khosla Ventures to democratize comprehensive health analytics.

ŌURA maintains its consumer market leadership with $200 million in Series D funding from True, Sequoia, and IVP, expanding beyond sleep tracking into comprehensive recovery and longevity monitoring.

Which of these startups received the largest investments in 2024 and 2025 so far, and from whom?

Altos Labs secured the largest single investment with $3 billion in Series A funding during 2024, led by Jeff Bezos, Yuri Milner, and Flagship Pioneering.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What total funding has gone into longevity startups in 2024 and 2025, and what are the expectations for 2026?

The longevity sector achieved unprecedented funding levels with $8.49 billion across 331 deals in 2024, representing a 220% increase over 2023 figures.

H1 2025 continues this momentum with multiple billion-dollar AI health investments, though longevity-specific totals are still being consolidated by industry analysts. The mega-round trend persists with companies like Minovia Therapeutics completing a $180 million SPAC transaction in June 2025.

Industry projections for 2026 anticipate the global longevity economy reaching a $27 trillion valuation, with venture funding expected to maintain its upward trajectory in platform technologies and translational therapeutics. Platform companies and AI-driven discovery tools are expected to capture the largest share of new investments.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

The geographic concentration remains heavily skewed toward the United States, which captured 84% of deal volume, while Europe accounted for 10% and Asia-Pacific for 3% of total investments.

Who are the major investors actively backing longevity startups, and under what conditions are they investing?

Khosla Ventures emerges as the most active institutional investor, leading multiple rounds in senotherapeutics and prevention platforms including Rubedo Life Sciences, Function Health, and Circulate Health.

Which geographic regions are seeing the most activity and growth in longevity startups?

The United States dominates the longevity startup ecosystem with 84% of global deal volume, concentrated primarily in four major hubs: San Francisco, Boston, New York City, and Seattle.

San Francisco leads with the highest concentration of cellular reprogramming and AI-driven platforms, hosting companies like Altos Labs and Function Health. Boston maintains its position as the biotech capital with strong pharmaceutical partnerships and academic connections to Harvard and MIT.

Europe accounts for 10% of deal activity, with London, Zurich, and Dublin emerging as key centers for regulatory-friendly longevity ventures targeting the European market's aging population demographics.

Asia-Pacific represents only 3% of current activity but shows rapid growth in Bangalore, Singapore, and Tel Aviv, particularly in AI-powered diagnostics and personalized medicine platforms targeting local market needs.

The geographic concentration reflects proximity to major research institutions, regulatory expertise, and access to specialized talent pools in biotechnology and artificial intelligence development.

Are large pharmaceutical companies or tech giants supporting or acquiring longevity startups?

Major pharmaceutical companies actively participate through dedicated venture arms, with Pfizer Ventures, Novartis Venture Fund, and Roche Venture Fund co-investing in Series A and B rounds while offering regulatory and commercial expertise.

Google maintains strategic partnerships through Calico and ongoing research funding in cellular reprogramming, while Amazon invests in consumer health and healthspan platforms that align with their broader healthcare initiatives.

Recent acquisition activity demonstrates increasing corporate interest: Juvenescence acquired AI-discovery firm Ro5 after its $76 million Series B-1, Function Health acquired whole-body MRI provider Ezra, and Longevity Health merged with diagnostics leader 20/20 BioLabs.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Tech giants focus on platform acquisitions that integrate with existing healthcare ecosystems, while pharmaceutical companies prioritize therapeutics with clear regulatory pathways and commercial potential in aging-related diseases.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which longevity startups have recently won awards, recognitions, or other notable accolades?

The Healthy Longevity Global Catalyst Awards distributed $50,000 grants to 15 U.S. innovators for transformative proposals addressing global aging challenges, highlighting the sector's academic recognition.

• Healthcare Asia Awards 2025 recognized BDMS Wellness Clinic's Scientific Wellness initiative as Health and Wellness Initiative of the Year
• WellFounded "Leaders in Health" Awards created categories specifically for founders, VCs, and providers driving health innovation
• World Economic Forum's "10 Start-ups to Watch" featured juli, Smplicare, TELL, Waterlily, and Zencey in AgeTech and AI biomarkers
• Taste For Life Longevity Essentials Awards recognized consumer supplements and devices supporting healthspan extension

These recognitions validate the sector's transition from experimental science to mainstream healthcare innovation, attracting institutional support and regulatory attention for evidence-based longevity interventions.

What major technological breakthroughs or R&D advances have longevity startups achieved in 2025?

Partial epigenetic reprogramming achieved significant milestones in mouse models, demonstrating lifespan extension while identifying tumor risks that guide safer clinical trial designs for human applications.

Insilico Medicine became the first company to advance an AI-designed drug molecule into human trials, validating generative AI discovery pipelines and establishing new regulatory precedents for machine-learning-derived therapeutics.

20/20 BioLabs' OneTest™ demonstrated multi-cancer early detection across twelve tumor types for under $200 per test, representing a breakthrough in affordable cancer screening technology.

Minovia Therapeutics advanced their mitochondrial augmentation stem-cell therapy MNV-201 into Phase II and Phase Ib trials, targeting both rare genetic disorders and age-related mitochondrial dysfunction.

Rubedo Life Sciences' Alembic platform leveraged single-cell multi-omics to identify novel GPX4 modulators, establishing new approaches to senolytic drug discovery through advanced computational biology methods.

Which innovations and breakthroughs are expected from longevity startups in 2026?

AI-personalized longevity "digital twins" will enable real-time healthspan tracking by integrating continuous biometric monitoring with predictive modeling for individual aging trajectories.

First epigenetic reprogramming clinical trials in humans are expected to commence, targeting specific age-related diseases rather than general aging, following successful safety validation in animal models.

Pan-omic predictive models combining epigenetics, glycomics, and metabolomics will achieve widespread clinical adoption for mortality and disease risk assessment, replacing traditional biomarker panels.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Regulatory breakthroughs will enable direct-to-consumer longevity therapeutics and diagnostics, expanding market access beyond traditional pharmaceutical distribution channels and accelerating consumer adoption of preventive interventions.

If you want actionable data about this market, you can download our latest market pitch deck here

What companies in adjacent industries are entering or influencing the longevity space?

Established biotech companies like Insilico Medicine, Human Longevity Inc., Juvenescence, Nuritas, and Elysium Health are expanding their platforms to address aging-specific therapeutic targets.

AI laboratories are making significant investments, with OpenAI executives including Sam Altman backing healthspan ventures, while companies like Abridge raise mega-deals for AI-powered clinical workflow optimization.

Fintech companies including Wealthfront and Betterment are adapting their robo-advisory platforms for "life-stage planning" that accommodates longer lifespans, creating financial products for 100-year lifecycles.

Consumer health platforms are expanding into molecular diagnostics and personalized supplements, leveraging existing customer relationships to offer longevity-focused products and services.

These cross-industry entrants bring complementary expertise in AI, consumer engagement, and financial services that accelerate longevity technology adoption and market penetration.

Which longevity startups stand out for other reasons such as partnerships, leadership, or unique technology?

Kyma Health differentiates through high-complexity biomarker assays that enable early frailty detection and personalized interventions, targeting the critical transition from healthy aging to age-related decline.

Liv Longevity Labs has developed a comprehensive wearable ecosystem combining continuous monitoring with AI risk stratification, offering more sophisticated analytics than traditional fitness trackers.

Clarence Health focuses on empathetic engagement platforms specifically designed for seniors, improving medication adherence and health outcomes through age-appropriate user interfaces and communication strategies.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

These companies demonstrate that longevity innovation extends beyond cellular reprogramming and AI drug discovery to include specialized applications addressing specific aging-related challenges and demographics.

What lessons can be learned from longevity startups that failed or stalled in the past two years?

BioAge Labs discontinued their obesity candidate after transaminitis events during clinical trials, highlighting the critical importance of comprehensive preclinical safety validation for longevity targets that may have unexpected systemic effects.

The longevity sector exhibits the typical 90% startup failure rate, with lack of product-market fit and undercapitalization remaining the primary causes of failure despite the sector's growth momentum.

Strategic misalignment represents a significant risk factor, particularly when companies overemphasize marketing hype with premature consumer offerings before establishing clinical proof-of-concept, which can erode credibility with investors and regulators.

Failed ventures often underestimate the lengthy development timelines required for longevity therapeutics, which typically require 10-15 years for clinical validation compared to traditional pharmaceuticals' 8-12 year timelines.

Successful longevity startups distinguish themselves through robust clinical validation pathways, strategic pharmaceutical partnerships, and the ability to translate cutting-edge science into scalable, regulated products that address real market needs.

Conclusion

Sources

1. Biospace - Six Startups Changing the Way We Age
2. Biospace - Longevity Biotech Takes Roots on NASDAQ
3. GeekWire - Circulate Health Raises $12M
4. Taste for Life - 2025 Longevity Essentials Awards
5. PR Newswire - Longevity Investment Doubled to $8.5BN
6. World Economic Forum - 10 Start-ups to Watch
7. Longevity Technology - Annual Investment Report 2024
8. Rock Health - H1 2025 Market Overview